Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 0.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 144,095 shares of the company’s stock after selling 1,172 shares during the period. Public Employees Retirement System of Ohio’s holdings in Moderna were worth $9,630,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp boosted its position in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Two Sigma Advisers LP acquired a new position in shares of Moderna in the third quarter worth $23,825,000. International Assets Investment Management LLC raised its stake in Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares during the last quarter. Finally, State of Michigan Retirement System boosted its stake in shares of Moderna by 201.9% during the 2nd quarter. State of Michigan Retirement System now owns 274,248 shares of the company’s stock worth $32,567,000 after purchasing an additional 183,407 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRNA. Oppenheimer downgraded shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Sanford C. Bernstein started coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Barclays reduced their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. TD Cowen lowered their price target on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Finally, Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $79.50.

Moderna Price Performance

MRNA stock opened at $42.82 on Friday. The firm has a market cap of $16.48 billion, a P/E ratio of -7.36 and a beta of 1.58. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The stock has a 50-day simple moving average of $48.62 and a 200-day simple moving average of $85.02.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.39) earnings per share. On average, equities analysts predict that Moderna, Inc. will post -9.32 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 3,379 shares of company stock valued at $158,195. Corporate insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.